Biotech entity
All 3 tracked stories fall under one category: pharma. Jefferies Financial Group is most often covered alongside Citigroup, which appears in 2 of these 3 stories. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Sep 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. Jefferies Financial Group is most often covered alongside Citigroup, which appears in 2 of these 3 stories. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.1 for that window. That works out to roughly 0.1 stories per week across a 171-day span. Jefferies Financial Group appears in 3 tracked Biotech stories published from February 21, 2026 through August 10, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 669 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jefferies Financial Group. Shared-story counts are live from our verified record — not editorial picks.
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Jefferies Financial Group is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
